- CEO
- Qingrong Sun
- Full Time Employees
- 1,271
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Liuyang National Eco & Technical Dev Zn Changsha HU China 410331
- IPO Date
- Sep 14, 2011
- Business
- Hunan Er-Kang Pharmaceutical Co., Ltd. (300267.SZ) manufactures and sells pharmaceutical excipients, active pharmaceutical ingredients (APIs), and finished drugs. The company produces over 120 types of pharmaceutical excipients including medicinal ethanol, medicinal glycerin, modified starch, starch capsule series products, citric acid series, sucrose, and compound excipients; 43 APIs such as dihydroxypropyl theophylline, sulbenicillin sodium, and calamine powder; and 148 finished drug approvals encompassing hemostatic, antitussive, bronchodilator, antibacterial injections, compound licorice tablets, methyl benzyl amoxicillin sodium injections, manna ghee pills, and pancreatic kinase enteric tablets.
Founded in 2003 and headquartered in Liuyang, Hunan province, China, the company operates as China's largest and most comprehensive pharmaceutical excipient provider with products exported to nearly 40 countries across Southeast Asia, Europe, and North America. It maintains 14 subsidiaries including Hunan Xiang Yi Kang Pharmaceutical Co., Ltd., Nanning Gui Zhilong Pharmaceutical Excipient Co., Ltd., and Hunan Er-Kang (Cambodia) Investment Co., Ltd., which supports an industrial park in Cambodia producing pharma-grade cassava starch, caffeine, folic acid, and sodium citrate. Er-Kang relies on national platforms like the National Pharmaceutical Excipients Engineering Technology Research Center and National Enterprise Technology Center for innovation in areas such as starch-based plant capsules, which hold global exclusive intellectual property rights with over 90 patents.
Recent developments include strong first-quarter 2025 financial performance with net income surging 869% year-on-year, plans for a share distribution of 10 shares for every 8 held in 2024, and passage of annual audits from major clients like Johnson & Johnson and Mentholatum in 2025. The company continues expanding its starch capsule market, including successful entry into the Middle East, while maintaining operations in new energy fund materials alongside its core pharmaceutical segments.